Clinical application of highly agglutinative staphylococcin in cancer treatment updates of the literature.

This review article summarized 100 published research papers and reviewed the application status of highly agglutinative staphylococcin in the clinical treatment of cancer. Highly agglutinative staphylococcin (HAS) derives from the superantigen of Staphylococcus aureus metabolite. Studies have shown that HAS can inhibit and kill tumors, repair tissues and cells, increase white blood cell count and improve the immune function. Its immunological effect acts through the following mechanism: activating T-cells and natural killer cells, enhancing phagocytes' phagocytosis and killing ability of lymphocytes, increasing white blood cell count in peripheral blood, repairing impaired histocytes, and inhibit the growth of tumor cells. Highly agglutinative staphylococcin is used in clinical treatment of tumors: intracavitary hyperthermic perfusion with single HAS is effective for malignant ascites; perfusion with HAS plus chemotherapeutics can remarkably improve the elimination rate of ascites. Highly agglutinative staphylococcin can also enhance the effect of and improve the response rate of chemotherapy and radiotherapy, and improve patients' immune function and relieve gastrointestinal reactions caused by radiotherapy and chemotherapy. Therefore, HAS is used to treat a malignant tumor, leucocytopenia, and malignant ascites, and relieve side effects caused by radiotherapy and chemotherapy and improve patients' immune function.